Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

Asad Bashey, Bridget Medina, Sue Corringham, Mildred Pasek, Ewa Carrier, Linda Vrooman, Israel Lowy, Scott R. Solomon, Lawrence E. Morris, H. Kent Holland, James R. Mason, Edwin P. Alyea, Robert J. Soiffer, Edward D. Ball

Blood (2009) 113 (7): 1581–1588.

https://doi.org/10.1182/blood-2008-07-168468

Published: 2009

Journal Articles

Clinical Trial of Therapeutic Blockade of CTLA4 with Ipilimumab in Patients with Relapse of Malignancy Following Allogeneic Hematopoietic Transplantation.

Asad Bashey, MD, PhD, Bridget Medina, Sue Corringham, RN, Mildred Pasek, Ewa Carrier, MD, Linda Vrooman, RN, Howard Streicher, MD, Israel Lowy, MD, Scott R. Solomon, MD, Lawrence E. Morris, MD, Kent Holland, MD, James R. Mason, MD, Robert J. Soiffer, MD, Edward D. Ball, MD

Blood (2007) 110 (11): 1646.

https://doi.org/10.1182/blood.V110.11.1646.1646

Published: 2007

Journal Articles

Analysis of Peripheral Blood CD4+/CD25 high Treg Cells and FOXP3 mRNA Expression in Patients Treated with Ipilimumab (Monoclonal Human Anti-CTLA4, MDX-010) for Relapse of Malignancy Following Allogeneic Hematopoietic Transplantation.

Jiehua Zhou, MD, Rui-kun Zhong, MD, Iveta Kalcheva, PhD, Bridget Medina, BS, Edward D. Ball, MD, Asad Bashey, MD

Blood (2006) 108 (11): 1735.

https://doi.org/10.1182/blood.V108.11.1735.1735

Published: 2006

Journal Articles

Phase I Study of Ipilimumab (Neutralizing Monoclonal Anti-CTLA4 Antibody) To Treat Relapse of Malignancy after Allogeneic Hematopoietic Stem Cell Transplantation: Evidence of Tumor Regression without Induction of GVHD.

Asad Bashey, MD, PhD, Bridget Medina, Sue Corringham, RN, Mildred Pasek, RN, Ewa Carrier, MD, Howard Streicher, MD, Israel Lowy, MD, James R. Mason, MD, Robert J. Soiffer, MD, Edward D. Ball, MD

Blood (2006) 108 (11): 410.

https://doi.org/10.1182/blood.V108.11.410.410

Published: 2006

Journal Articles

Phase I Study of a Neutralizing Monoclonal Anti-CTLA4 Antibody (MDX-010) in Patients with Relapse of Malignancy after Allogeneic Hematopoietic Stem Cell Transplantation.

Asad Bashey, MD, PhD, Bridget Medina, Sue Corringham, RN, Mildred Pasek, Ewa Carrier, MD, Howard Streicher, MD, Israel Lowy, MD, PhD, James Mason, MD, Robert J. Soiffer, MD, Edward D. Ball, MD

Blood (2005) 106 (11): 2017.

https://doi.org/10.1182/blood.V106.11.2017.2017

Published: 2005

Journal Articles

BEAM Versus CEB Conditioning for Autologous Transplantation in Patients with Non-Hodgkin’s Lymphoma and Hodgkin’s Disease: A Single Center Comparative Study of 219 Patients.

Asad Bashey, MD, PhD, Oralia Loza, Bridget Medina, Katherine Keesee, PharmD, Sue Corringham, RN, Januario Castro, MD, Peter Holman, MD, Thomas A. Lane, MD, Edward D. Ball, MD, Ewa Carrier, MD

Blood (2005) 106 (11): 2079.

https://doi.org/10.1182/blood.V106.11.2079.2079

Published: 2005

Journal Articles

Intermediate Dose Cyclophosphamide Followed by Sequential GM-CSF and G-CSF: An Efficient and Predictable PBPC Mobilization Regimen for Autografting: A Single Center Study of Two Hundred and Thirty Patients.

Thomas A. Lane, MD, Lin Liu, PhD, Anita Ihasz, Bridget Medina, Sue Corringham, RN, Peter Holman, MD, Ewa Carrier, MD, Januario Castro, MD, Edward D. Ball, MD, Asad Bashey, MD

Blood (2005) 106 (11): 5281.

https://doi.org/10.1182/blood.V106.11.5281.5281

Published: 2005

NARROW

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

Clinical Trial of Therapeutic Blockade of CTLA4 with Ipilimumab in Patients with Relapse of Malignancy Following Allogeneic Hematopoietic Transplantation.

Analysis of Peripheral Blood CD4+/CD25 high Treg Cells and FOXP3 mRNA Expression in Patients Treated with Ipilimumab (Monoclonal Human Anti-CTLA4, MDX-010) for Relapse of Malignancy Following Allogeneic Hematopoietic Transplantation.

Phase I Study of Ipilimumab (Neutralizing Monoclonal Anti-CTLA4 Antibody) To Treat Relapse of Malignancy after Allogeneic Hematopoietic Stem Cell Transplantation: Evidence of Tumor Regression without Induction of GVHD.

Phase I Study of a Neutralizing Monoclonal Anti-CTLA4 Antibody (MDX-010) in Patients with Relapse of Malignancy after Allogeneic Hematopoietic Stem Cell Transplantation.

BEAM Versus CEB Conditioning for Autologous Transplantation in Patients with Non-Hodgkin’s Lymphoma and Hodgkin’s Disease: A Single Center Comparative Study of 219 Patients.

Intermediate Dose Cyclophosphamide Followed by Sequential GM-CSF and G-CSF: An Efficient and Predictable PBPC Mobilization Regimen for Autografting: A Single Center Study of Two Hundred and Thirty Patients.

Email alerts

ASH Publications

American Society of Hematology

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

Clinical Trial of Therapeutic Blockade of CTLA4 with Ipilimumab in Patients with Relapse of Malignancy Following Allogeneic Hematopoietic Transplantation.

Analysis of Peripheral Blood CD4+/CD25 high Treg Cells and FOXP3 mRNA Expression in Patients Treated with Ipilimumab (Monoclonal Human Anti-CTLA4, MDX-010) for Relapse of Malignancy Following Allogeneic Hematopoietic Transplantation.

Phase I Study of Ipilimumab (Neutralizing Monoclonal Anti-CTLA4 Antibody) To Treat Relapse of Malignancy after Allogeneic Hematopoietic Stem Cell Transplantation: Evidence of Tumor Regression without Induction of GVHD.

Phase I Study of a Neutralizing Monoclonal Anti-CTLA4 Antibody (MDX-010) in Patients with Relapse of Malignancy after Allogeneic Hematopoietic Stem Cell Transplantation.

BEAM Versus CEB Conditioning for Autologous Transplantation in Patients with Non-Hodgkin’s Lymphoma and Hodgkin’s Disease: A Single Center Comparative Study of 219 Patients.

Intermediate Dose Cyclophosphamide Followed by Sequential GM-CSF and G-CSF: An Efficient and Predictable PBPC Mobilization Regimen for Autografting: A Single Center Study of Two Hundred and Thirty Patients.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only